<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Corvus Pharmaceuticals Inc — News on 6ix</title>
    <link>https://6ix.com/company/corvus-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Corvus Pharmaceuticals Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 23 Apr 2026 11:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/corvus-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835599c78dffbe2df0eb1e2.webp</url>
      <title>Corvus Pharmaceuticals Inc</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc</link>
    </image>
    <item>
      <title>Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-appoints-andrew-c-chan-md-phd-to-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-appoints-andrew-c-chan-md-phd-to-board-of-directors</guid>
      <pubDate>Thu, 23 Apr 2026 11:30:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that Andrew C. Chan, M.D., Ph.D., has been appointed to the Company’s Board of Directors. Dr. Chan recently served as Senior Vice President, Research Biology during a distinguished 25 year career at Genentech. In this role, he led biological research across all therapeutic areas, contributing to the development of several FDA-app</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-to-host-investor-and-analyst-meeting-on-may-14-2026-to-highlight-soquelitinib-data-being-presented-at-the-society-for-investigative-dermatology-sid-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-to-host-investor-and-analyst-meeting-on-may-14-2026-to-highlight-soquelitinib-data-being-presented-at-the-society-for-investigative-dermatology-sid-annual-meeting</guid>
      <pubDate>Tue, 21 Apr 2026 11:30:00 GMT</pubDate>
      <description>Two oral presentations including late-breaker at SID Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free remissions Investor and analyst meeting scheduled for 1:30 pm ET (12:30 pm CT) on May 14, 2026 Company to report first quarter 2026 financial results on May 7, 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceu</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Thu, 12 Mar 2026 20:01:00 GMT</pubDate>
      <description>Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated soquelitinib atopic dermatitis Phase 2 trial Completed public offering raising net proceeds of $189 million, extending cash runway into the second quarter of 2028 Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Corvus</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026-28</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026-28</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals,</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
      <pubDate>Mon, 23 Feb 2026 21:01:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at Oppenheimer 36th Annual Healthcare Life Sciences Conference which is being held virtually. The presentation will be on Thursday, February 26, 2026 at 2:40pm ET. A webcast of the presentation will be available liv</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-announces-closing-upsized-220000399</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-announces-closing-upsized-220000399</guid>
      <pubDate>Fri, 23 Jan 2026 22:00:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public offering of 9,085,778 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,185,101 additional shares, at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting disco</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-announces-pricing-upsized-035300192</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-announces-pricing-upsized-035300192</guid>
      <pubDate>Thu, 22 Jan 2026 03:53:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 shares of its common stock at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $175.0 million. A</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-announces-proposed-public-210100186</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-announces-proposed-public-210100186</guid>
      <pubDate>Tue, 20 Jan 2026 21:01:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the offering will be offered by Corvus. In additi</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-announces-positive-data-120000892</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-announces-positive-data-120000892</guid>
      <pubDate>Tue, 20 Jan 2026 12:00:00 GMT</pubDate>
      <description>Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment 75% of soquelitinib patients achieved EASI 75, 25% achieved EASI 90 and 33% achieved IGA 0/1 Cohort 1-4 have demonstrated positive safety and efficacy results in patients who have received prior systemic therapy including patients who are treatment resistant Company to host conference call and webcast today at 8:00 am ET / 5:00 am PT SOUTH SAN FRANCISC</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-announce-results-cohort-210100653</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-announce-results-cohort-210100653</guid>
      <pubDate>Fri, 16 Jan 2026 21:01:00 GMT</pubDate>
      <description>Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PTSOUTH SAN FRANCISCO, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am PT) to report the results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in pa</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-confirms-plans-announce-133000118</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-confirms-plans-announce-133000118</guid>
      <pubDate>Mon, 05 Jan 2026 13:30:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis in the second half of January 2026. Given the proximity to our upcoming data, we are cancelling all previously planned conference attenda</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-presents-final-data-153000732</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-presents-final-data-153000732</guid>
      <pubDate>Mon, 08 Dec 2025 15:30:00 GMT</pubDate>
      <description>Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 trial in atopic dermatitis and potential expansion into other immune and inflammatory diseases Highlights ITK inhibition novel mechanism of action affecting T cell receptor signaling and T cell differentiation Presented in an oral session at the 67th Am</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-provides-business-reports-210100705</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-provides-business-reports-210100705</guid>
      <pubDate>Tue, 04 Nov 2025 21:01:00 GMT</pubDate>
      <description>Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January Soquelitinib atopic dermatitis phase 2 trial on track to initiate in early Q1 2026 Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open; final Phase 1/1b results accepted for oral presentation at the American Society</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting &amp; Exposition</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-present-final-data-140200368</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-present-final-data-140200368</guid>
      <pubDate>Mon, 03 Nov 2025 14:02:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma will be presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting &amp; Exposition, which is taking place December 6-9, 2025 in Orlando, FL. Details regarding the oral presentation are as follows: Session Name:</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-present-guggenheim-2nd-113000111</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-present-guggenheim-2nd-113000111</guid>
      <pubDate>Fri, 31 Oct 2025 11:30:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is being held in Boston, MA. The fireside chat will be on Monday, November 10, 2025 at 8:30 am ET. A webcast of the fireside chat w</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-business-third-quarter-200100864</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-business-third-quarter-200100864</guid>
      <pubDate>Tue, 28 Oct 2025 20:01:00 GMT</pubDate>
      <description>Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTSOUTH SAN FRANCISCO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 4, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domesti</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-announces-presentation-interim-140000228</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-announces-presentation-interim-140000228</guid>
      <pubDate>Fri, 17 Oct 2025 14:00:00 GMT</pubDate>
      <description>Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) Interim data shows triplet therapy with ciforadenant, ipilimumab and nivolumab is feasible and well tolerated; longer follow-up with patients still on therapy needed to determine potential benefit of blocking adenosine signaling SOUTH SAN FRANCISCO, Calif.,, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals Appoints David Moore to Board of Directors</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-appoints-david-moore-200100447</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-appoints-david-moore-200100447</guid>
      <pubDate>Thu, 02 Oct 2025 20:01:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., has been appointed to the company’s Board of Directors. Mr. Moore brings a wealth of experience from his 27-year career in the industry, including broad expertise across strategy, commercial, market access, business de</description>
    </item>
    <item>
      <title>Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-provides-business-reports-200100454</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/corvus-pharmaceuticals-provides-business-reports-200100454</guid>
      <pubDate>Thu, 07 Aug 2025 20:01:00 GMT</pubDate>
      <description>Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8 Enrollment ongoing in Phase 1 trial extension cohort 4 exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period; Phase 2 trial on track to initiate before end of year Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T cell l</description>
    </item>
    <item>
      <title>BioMarin Announces Appointment of Ian T. Clark to Board of Directors</title>
      <link>https://6ix.com/company/corvus-pharmaceuticals-inc/news/biomarin-announces-appointment-of-ian-t-clark-to-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/corvus-pharmaceuticals-inc/news/biomarin-announces-appointment-of-ian-t-clark-to-board-of-directors</guid>
      <pubDate>Fri, 01 Aug 2025 13:00:00 GMT</pubDate>
      <description>BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Ian T. Clark to the company&apos;s Board of Directors, effective today, August 1, 2025.</description>
    </item>
  </channel>
</rss>